Skip to main content

    Vi uppgraderar Mina sidor under maj

    Boka, videobesök och chatt fungerar som vanligt i HLTHY medan vi bygger nästa version av Mina sidor.

    Öppna HLTHY för bokning, video och chatt
    The obesity clinic
    Menu closed
    Oral Semaglutide
    Tablets
    GLP-1
    +1

    Medical guide

    High-Dose Oral Semaglutide: What Do We Know in 2026?

    Oral semaglutide at higher doses has drawn attention as a possible obesity treatment. This article explains what the studies show, what is actually available, and what still remains uncertain.

    minutes reading time

    6 min

    Updated

    9 April 2026

    Reviewed by

    Dr. Dorél Lehrer

    Content

    Rx education

    High-dose oral semaglutide tablets and obesity research

    Dr. Dorél Lehrer

    Licensed Physician

    Quick answer

    High-dose oral semaglutide has shown promising trial results for weight loss, but research findings, market approval and real access in Sweden are not the same thing. In 2026 it is still important to separate study data from established clinical availability.

    DD

    Dr. Dorél Lehrer

    Licensed Physician

    Medical Director at Viktenheten
    Experienced in medical weight management

    Verifierad av Socialstyrelsen

    Medicinskt granskad: 23 March 2026

    Medical information, not medicine advertising

    This article is educational and does not replace individual care. Which medicine may be relevant is decided by a licensed doctor after medical assessment. Prescription issuing is included only when a doctor decides it is medically appropriate.

    Medicinskt granskad av Dr. Dorél Lehrer, 23 March 2026. Innehållsrisk: rx-education.

    Searches for oral semaglutide 50 mg usually reflect interest in a more effective tablet option for obesity. Trial results, regulatory approval and real availability in Sweden are not the same thing. Here is what is known in 2026.

    What is available today?

    Rybelsus is oral semaglutide approved for type 2 diabetes, while a high-dose tablet specifically established for obesity is still a separate question.

    What did the OASIS studies test?

    The OASIS program studied higher oral semaglutide doses and reported clinically meaningful weight-loss results on a group level.

    Why research does not equal routine care

    Before a treatment becomes a normal Swedish option, regulators, pricing systems, supply chains and prescribing routines all need to be in place.

    How do tablets compare with injections?

    Tablets may feel easier for some patients, but adherence, absorption, dose strength and total effect still have to be weighed against injectable alternatives.

    Sources and Further Reading

    Denna artikel är medicinsk information skriven av Dr. Dorél Lehrer, Licensed Physician. Eventuell behandling sker efter individuell bedömning av legitimerad läkare.

    Read about medical assessment

    Related Articles

    Keep learning

    View all articles

    Discover more

    Care Program

    Read about our medical weight treatment programme

    FAQ

    Answers to common questions about GLP-1

    Book appointment

    Book a doctor consultation for weight treatment